Amgen's Q1 Earnings: Turnaround or More Dips?

Amgens Q1 earnings report tomorrow could spark a biotech sector turnaround, with analysts expecting a 4.3% revenue growth, up from last years 10% surge. Despite recent revenue slips, Amgens average analyst price target of $352.73, well above its current $338.80, and the strong investor mood in biotech, could drive a positive outcome. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/080a4d8e55053318